Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Autoimmune and Inflammatory Disorders, and Eosinophilic Esophagitis.
Adherent-invasive <i>Escherichia coli</i> in Crohn's disease: the 25th anniversary.
Darvadstrocel in Patients With Crohn's Disease With Complex Perianal Fistulas: The ADMIRE CD II Phase 3 Randomized Trial.
Crohn's disease is an obstructive lymphangitis.
Screening for preclinical Crohn's disease based on capsule endoscopy is not yet ready.
Mucosal glycans: key drivers of the development of inflammatory bowel disease and a potential new therapeutic target.
Tunnel vision: rethinking local therapy for perianal fistulas in Crohn's disease.
Artificial intelligence enhances screening efficiency for inflammatory bowel disease clinical trials: a prospective study.
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials.
Patients' attitudes to disease prevention in inflammatory bowel disease: a US-based survey.
Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.
Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study
Gut microbiota strain richness is species specific and affects engraftment.
Targeting the Interleukin 23 Pathway in Inflammatory Bowel Disease.
Emerging role of environmental pollutants in inflammatory bowel disease risk, outcomes and underlying mechanisms.
Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials.
Adherent-invasive <i>Escherichia coli</i> in Crohn’s disease: the 25th anniversary
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis.
Alterations in mucosa branched <i>N</i>-glycans lead to dysbiosis and downregulation of ILC3: a key driver of intestinal inflammation.
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY)
Reparative immunological consequences of stem cell transplantation as a cellular therapy for refractory Crohn's disease.
Endoscopic Response Reduces the Risk of Subsequent Pouchitis in Patients With Crohn's Disease-Like Pouch Inflammation.
A Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 7 Predicts Disease Progression.
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial.
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint
Advanced Therapies in Crohn's Disease: A Critical Appraisal of Location-based Efficacy.